Overall market sentiment has been high on AIM ImmunoTech Inc (AIM) stock lately. AIM receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With AIM Stock Today?
AIM ImmunoTech Inc (AIM) stock has fallen -5.05% while the S&P 500 is up 0.06% as of 10:25 AM on Tuesday, Dec 22. AIM is lower by -$0.11 from the previous closing price of $2.18 on volume of 1,534,891 shares. Over the past year the S&P 500 has risen 14.67% while AIM is up 350.00%. AIM lost -$0.44 per share in the over the last 12 months.
To screen for more stocks like AIM ImmunoTech Inc click here.
More About AIM ImmunoTech Inc
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Click Here to get the full Stock Score Report on AIM ImmunoTech Inc (AIM) Stock.
